Novartis Q4 Results
↑
Content
Click below to navigate
through the document
ganaplacide/lumefantrine - Non-artemisinin
plasmodium falciparum inhibitor
↓
Company overview
Financial review
Conclusions
NCT05842954 KALUMA (CKLU156A12301)
Indication
Phase
Patients
Malaria, uncomplicated
Phase 3
1500
PCR-corrected adequate clinical and parasitological response (ACPR) at day 29
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
Oncology
Other
> Global Health
Abbreviations
Primary
Outcome
Measures
Arms
Intervention
Arm 1 experimental: KLU156 oral; 400/480 mg is the dose for patients with a
bodyweight ≥ 35kg. Patients < 35kg will take a fraction of the dose according to
weight group as defined in the protocol.
Arm 2 active comparator: Coartem, oral, dosing will be selected based on patient's
body weight as per product's label.
Adults and children ≥ 5 kg Body Weight with uncomplicated P. Falciparum Malaria
Target Patients
Readout
Milestone(s)
2025
Publication
TBD
References
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
84View entire presentation